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ments. The albumin excretion rate was significantly higher inGlomerulosclerosis and progression: Effect of subantihyper-
untreated SNX than in sham; it was significantly lower in alltensive doses of  and  blockers.
treated SNX groups.Background. Uremia is characterized by inadequately in-
Conclusion. The beneficial effect of non-hypotensive dosescreased sympathetic activity. Sympathetic overactivity is involved
of  and  blockers and their combination on renal morphologyin the genesis of hypertension in uremia, but its potential role
and albuminuria in the model of renal ablation argue for aon progression has not been well investigated. To address this
blood pressure-independent role of sympathetic overactivityissue, the effect of subantihypertensive doses of an  blocker
in the genesis of progression. In addition, the beneficial effectand a  blocker, and their combination on renal morphology
of adrenergic receptor blockade indicates that a substantialand on albuminuria were investigated in the model of the
part is not mediated by sympathetic cotransmitters such assubtotally nephrectomized rat.
adenosine 5-triphosphate (ATP) and neuropeptide Y (NPY).Methods. Male Sprague-Dawley rats were subjected to sur-
gical ablation (SNX) or sham operation (sham). Three days
after surgery groups were treated either with phenoxybenzamine
(PBZ, 5 mg/kg body weight/day), metoprolol (MET, 150 mg/kg
The role of the renin-angiotensin (RAS) and endo-body weight/day) or their combination (PBZ 2.5 mg/kg body
thelin (ET) systems in progression of renal failure hasweight/day  MET, 50 mg/kg body weight/day). Renal mor-
phology was evaluated after 12 weeks by quantitative histology, been thoroughly investigated [1–3]. Although it is known
immunohistochemistry, and electron microscopy. Urine albu- that the sympathetic nervous system is overactive in ure-
min excretion and kidney endothelin-1 (ET-1), platelet-derived mic rats [4] and patients [5], and that this sympathetic
growth factor (PDGF), and transforming growth factor-
overactivity contributes to the genesis of hypertension(TGF-) mRNA expression were assessed.
in renal failure [6–9], the potential role of sympatheticResults. Systolic blood pressure was significantly higher in
all SNX groups compared with sham-operated controls with overactivity on progression of renal failure has not been
no difference in the SNX groups. The number of glomeruli per well investigated. The kidney contains chemoreceptors
left kidney was reduced from 30,904  3212 to 17,480  2341 and mechanoreceptors that are presumably stimulated
by SNX (43.5%). Mean glomerular volume increased from
in the lesioned kidney [10]. Afferent signals travel to2.63  0.7 in untreated sham operated to 4.11  0.48 m3
the central nervous system [11], and it has been well106 in untreated SNX (56.3%). The glomerulosclerosis index
did not change in SNX  PBZ rats, but was significantly lower documented that the activity of hypothalamic centers
in SNX  MET (0.56  0.14) and particularly SNX  PBZ  controlling sympathetic tone is increased [12]. Moreover,
MET rats (0.49  0.11) than in untreated SNX (0.74  0.24). noradrenaline release from renal cortex of subtotally
Glomerular capillary length density (LV) as a sensitive index nephrectomized rats is enhanced, suggesting an alteredof capillary obliteration was significantly lower in SNX and
presynaptic modulation of neurotransmitter release withinalmost normalized in the three intervention groups. The same
was true for the mean podocyte number per glomerulus. Glomer- the kidney [13]. A complementary cause of sympathetic
ular ultrastructure in SNX was largely preserved by all treat- activation in chronic renal failure might be elevated lep-
tin [14] and angiotensin II concentrations [15].
Clinical studies in diabetic patients documented thatKey words: subtotal nephrectomy, sympathetic nerve activity, renal
 blockers are highly effective in retarding progressionfailure, albuminuria, progressive renal disease, kidney lesions, phenoxy-
benzamine, metoprolol. of renal failure [16, 17]. It has been assumed that this
effect is largely nonspecific and can be accounted for byReceived for publication September 11, 2000
lowering systemic blood pressure (BP). A potential bloodand in revised form February 19, 2001
Accepted for publication May 3, 2001 pressure–independent effect of the blockade of the effer-
ent sympathetic nerve system, particularly  receptor- 2001 by the International Society of Nephrology
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mediated activation of the RAS has not been excluded, of the left kidney. To standardize the procedure, an
amount of cortex corresponding to 75% of the weighthowever. Our previous study showed that moxonidine,
a central sympatholytic agent, given in doses that failed of the resected right kidney was removed [13, 18, 19].
Sham operation was performed as described previouslyto lower systemic blood pressure had a beneficial effect
on progression [13]. Since imidazoline receptors that are in this article. Forty-eight hours after the second opera-
tion administration of medication was started. The ani-activated by moxonidine are found not only in the central
nervous systems but also in the kidney, direct renal ef- mals were offered food pellets containing the respective
drugs. Water and food consumption were monitoredfects of moxonidine cannot be firmly excluded. In addi-
tion, a global blockade of sympathetic activity did not daily, and the amount of food offered was adjusted ac-
cordingly in order to keep the drug dosage constant.allow us to distinguish whether the effects of sympathetic
overactivity were due to the release of catecholamines With this protocol, food consumption was comparable
between the groups, as documented by body weightsor of sympathetic cotransmitters, particularly adenosine
5-triphosphate (ATP) and neuropeptide Y (NPY). These at the end of the experiment. Before terminating the
experiment, animals were placed in metabolic cages andcotransmitters are known to affect not only renal hemo-
dynamics, but also events relevant for progression, for 24-hour urine was collected for determination of urine
volume and albumin excretion.example, renal cell proliferation.
To clarify these points that had been left unanswered
Blood pressure measurementsin our earlier moxonidine study, the present study was
designed so that sham-operated and subtotally nephrec- Mean arterial blood pressure (MAP), systolic arterial
blood pressure (SAP) and diastolic arterial blood pres-tomized rats could be compared using an intervention with
either the  blocker phenoxybenzamine, the  blocker sure (DAP), heart rate (HR, derived from the peak sys-
tolic blood pressure signal, min1), and motor activity ofmetoprolol, or a combination of the  and  blocker in
non-hypotensive doses. The kidneys were examined using animals (MA, U per 10 min) were measured using a
telemetry system (Data Sciences Inc., St Paul, MN, USA)stereological and molecular biological techniques; uri-
nary albumin excretion was assessed as an in vivo index in four animals per group during the entire 12-week study
period [20]. Transmitters (TL 10-M2-C50 PE, TL11-M2-of glomerular damage.
C50-PXT) were implanted in the abdominal aorta. For
electrocardiography, two electrodes were implanted sub-
METHODS
cutaneously. Receivers (RLA 1000, RA 1000) were placed
Animals underneath the cage. The maximum transmitter range
was 40 cm. Implantation of the telemetry transmitterMale 200 g Sprague-Dawley rats (SD) were housed
in single cages at constant room temperature (20	C) and was performed as described elsewhere [13].
In addition, systolic blood pressure was measured inhumidity (75%) under a controlled light-dark cycle. The
rats were fed a diet containing 40 g protein and 0.6 g all animals at weeks 1, 2, and 11 using tail plethysmo-
graphy in conscious animals [13].NaCl per 100 g (Altromin Co., Lage/Lippe, Germany).
After a three-day adaptation period, the animals were
Urinary albumin measurementsrandomly allotted to seven groups (N
 5 to 12 per group).
The sham-operated control groups comprised: (1) un- Urinary albumin was measured using the microplate
technique (Sandwich ELISA) as described in detail [18].treated (sham), (2) phenoxybenzamine (5 mg/kg body
weight/day; sham PBZ), and (3) metoprolol (150 mg/kg
Tissue preparationbody weight/day; sham  MET). The subtotally nephrec-
tomized groups included: (4) untreated (SNX), (5) phen- Perfusion fixation and tissue sampling for morphomet-
ric and stereological investigations. After 12 weeks, bloodoxybenzamine (5 mg/kg body weight/day; SNX  PBZ),
(6) metoprolol (150 mg/kg body weight/day; SNX  samples were obtained and the experiment was termi-
nated by retrograde perfusion fixation via the abdominalMET), and (7) combination (SNX PBZMET; phen-
oxybenzamine 2.5 mg/kg body weight/day and metoprolol aorta as described in detail elsewhere [13, 18, 19]. For
morphometric and stereological measurements, animals50 mg/kg body weight/day).
Groups 1 through 3 were sham-operated whereas were perfused with 3% glutaraldehyde. The kidneys
were removed, weighed, and dissected in a plane perpen-groups 4 through 7 underwent two-step subtotal surgical
nephrectomy: In a first operation, the right kidney was dicular to the interpolar axis, yielding slices of 1 mm
width. Ten small pieces of each kidney were selected byremoved under general anesthesia (ketamin, xylazin)
and was weighed. Sham operation consisted of decapsu- area weighted sampling for Epon-Araldite embedding
[13, 18, 19]. The remaining tissue slices were embeddedlation of the kidney, taking special care not to damage
the adrenals. After one week, the subtotal nephrectomy in paraffin; 4 m sections were taken and stained with
hematoxylin/eosin (HE) and PAS. Five of the resin blockswas completed by resecting the lower and upper poles
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Table 1. Animal data
Weight of
Body left kidney Serum Serum
Systolic Urinary albuminweight (remnant) creatinine urea
blood pressurea excretion Hemoglobin
Groups mm Hg g mg/dL mg/24 h, week 12 g/dL
Sham operated
Untreated (N
8) 9114.0 41626.0 1.530.29 0.580.30 35.67.44 0.290.21 14.81.10
PBZ (N
5) 8812.6 41317.1 1.640.05 0.540.02 39.09.70 2.50.48 14.30.46
MET (N
5) 867.5 37938.6 1.590.29 0.560.03 48.38.66 3.80.11 13.60.17
SNX
Untreated (N
10) 11314.4b 42716.8 2.290.31b 0.820.09b 89.231.1b 13373.6b 14.11.06
PBZ (N
10) 11323.5b 41127.8 2.250.58b 0.780.13b 105.836.6b 64.250.3bc 14.71.36
MET (N
10) 10910.7b 40221.3 2.410.45b 0.760.09b 106.923.3 53.340.3bc 13.91.13
PBZMET (N
12) 11017.4b 41231.2 2.060.36b 0.770.08b 90.824.8b 43.735.7bc 13.70.99
P value ANOVA 0.05 NS 0.001 0.05 0.05 0.05 NS
Abbreviations are: PBZ, phenoxybenzamine; MET, metoprolol.
a Week 11 by tail plethysmography
b P  0.05 vs. all sham groups
c P  0.05 vs. untreated SNX
were randomly selected, from which semithin sections sclerosis involving less than 50% of the glomerular tuft;
(0.5 m) were prepared and stained with methylene blue grade 3, diffuse glomerular hyalinosis/sclerosis involving
and basic fuchsin. Subsequently, the paraffin and semi- more than 50% of the tuft; and grade 4, diffuse glomeru-
thin sections were investigated by means of morphome- losclerosis with total tuft obliteration and collapse. The
try and stereology [13, 18, 19]. resulting index in each animal was expressed as a mean
For qualitative electron microscopic investigation, sev- of all scores obtained.
eral ultrathin sections (0.08m) per animal were prepared Tubulointerstitial and vascular damage was assessed on
and stained with uranyl acetate/lead citrate. Sections were PAS-stained paraffin sections at a magnification of 100
then investigated using a Zeiss electron microscope EM using similar semiquantitative scoring systems [13, 18].
10 (Zeiss Co., Oberkochen, Germany) at various magni- For determination of the tubulointerstitial damage score,
fications. 10 fields per kidney were randomly sampled and graded
Immunohistochemistry, RT-PCR, and in situ hybrid- as follows: grade 0, no change; grade 1, lesions involving
ization. For immunohistochemistry, RT-PCR and in situ less than 25% of the area; grade 2, lesions affecting 25
hybridization ice-cold NaCl was used as the perfusion to 50%; grade 3, lesions involving more than 50%; and
solution [13, 18]. The kidneys were dissected into three grade 4, involving (almost) the entire area. Similarly, for
pieces perpendicular to the interpolar axis. One piece the vascular damage score the following scheme was
was fixed with buffered paraformaldehyde and embed- adopted: grade 0, no wall thickening; grade 1, mild wall
ded in paraffin. Four-micrometer thick sections were cut thickening; grade 2, moderate wall thickening; grade 3,
and used for immunohistochemistry. The remaining two severe wall thickening; and grade 4, fibrinoid necrosis of
pieces were frozen in liquid nitrogen and used for in situ the vascular wall.
hybridization (frozen sections) and RT-PCR. Glomerular geometry. Paraffin sections (HE and PAS
stain, light microscopy using various magnifications) were
Morphological investigations of the kidney used. Briefly, the glomerular geometry was analyzed as
follows: Volume density (VV) of glomeruli and area den-Indices of renal damage (glomerulosclerosis, tubulo-
interstitial, and vascular damage). The degree of sclerosis sity of glomerular tuft (AAT) were measured by point
counting according to PP 
 AA 
 VV at a magnificationwithin the glomerular tuft as an index of progression was
determined on PAS-stained paraffin sections adopting of 400 on HE sections [13, 18, 19]. In addition, the
number of glomeruli per area (NA) was counted. Thethe semiquantitative scoring system proposed by el Nahas
et al [21]. Using light microscopy at a magnification of total area of the glomerular tuft (AT) was then deter-
mined as AT 
 AAT  ACortex. The number of glomeruli400, the glomerular score of each animal was derived
as the mean of 100 glomeruli. The severity of glomerulo- per volume (NV) and the volume density (VV) of glomer-
uli were calculated using the formula: NV 
 k/  N1.5A /sclerosis was expressed on an arbitrary scale from 0 to 4
[13, 19, 21]. The glomerular score for individual glomer- V0.5V with k 
 1 and  
 1.382. The total number of
glomeruli was derived from the total volume of the renaluli was: grade 0, normal glomerulus; grade 1, presence
of mesangial expansion/thickening of the basement mem- cortex and the number of glomeruli per cortex volume:
Nglom 
 NV  VCortex.The mean glomerular tuft volumebrane; grade 2, mild/moderate segmental hyalinosis/
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Fig. 1. Representative glomerular changes in
untreated (D) and treated surgical ablation
(SNX) groups (E–G ) compared with un-
treated (A) and treated (B and C ) sham-oper-
ated controls. Untreated (D) and phenoxy-
benzamine (E)-treated SNX had advanced
glomerulosclerosis with diffuse thickening of
the mesangium due to mesangial matrix expan-
sion and tuft adhesion compared to the normal
glomerular morphology in untreated (A) and
treated sham rats (B and C). These glomerular
structural changes were less pronounced in
metoprolol (F), particularly in the combina-
tion (G)-treated SNX. Magnification: 1:100;
A, untreated sham; B, phenoxybenzamine-
treated sham; C, metoprolol-treated sham; D,
untreated SNX; E, phenoxybenzamine-treated
SNX; F, metoprolol-treated SNX; G, combi-
nation-treated SNX.
was determined according to v 
 /k  A1.5T with  
 using the point counting method and a 100 point eyepiece
(Integrationsplatte II; Zeiss Co.) at a magnification of1.382 and k 
 1 [13, 18, 19].
Analysis of glomerular capillarization and cellularity on 1000 (oil immersion) as previously described [22].
Briefly, the length density (LV) of glomerular capillar-semithin sections. On five semithin sections per animal,
glomerular capillarization and cellularity were analyzed ies was determined according to the standard stereologi-
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Table 2. Renal morphology
Indices of renal damage Glomerular counts and geometry
Glomerulosclerosis Tubulointerstitial Vascular Number of glomeruli per Mean glomerular volume
Groups index index index left kidney (remnant) 10 6 lm3
Sham operated
Untreated (N
8) 0.070.02 0.040.04 0.070.02 30,9043212 2.630.70
PBZ (N
5) 0.060.02 0.010.01 0.100.05 34,4075034 2.400.55
MET (N
5) 0.050.02 0.030.03 0.080.03 30,3134350 2.680.21
SNX
Untreated (N
10) 0.740.24a 0.940.56a 0.690.27a 17,4802341a 4.110.48a
PBZ (N
10) 0.640.21ac 1.000.49ac 0.670.17ac 21,6243860ab 3.320.45ab
MET (N
10) 0.560.14ab 1.070.37a 0.680.25ac 20,4394391a 3.720.56a
PBZMET (N
12) 0.490.11ab 0.660.38a 0.490.14a 19,3263612a 3.410.63ab
P value ANOVA 0.001 0.001 0.001 0.001 0.001
Abbreviations are: PBZ, phenoxybenzamine; MET, metoprolol.
a P  0.05 vs. all sham groups
b P  0.05 vs. untreated SNX
c P  0.05 vs. SNX  PBZ  MET
cal formula, LV 
 2QA (with QA being the number of derived growth factor (PDGF), known to be involved in
capillary transects per area of the capillary tuft) [22]. the pathophysiology of progressive glomerulosclerosis,
Total length of glomerular capillaries per one kidney was investigated.
(Ltotal) was then derived from LV and the total glomerular RT-PCR for measurement of ET-1, TGF-b, and PDGF
volume (Vglom) with Vglom 
 VVglom  Vcortex. mRNA: RNA isolation. Total RNA was isolated from fro-
Glomerular cellularity (podocytes, mesangial and en- zen tissue samples of rat kidneys using Trizol (GIBCO
dothelial cells) was assessed by stereological techniques BLR Co., Eggenstein, Germany), and the integrity check
[22] in at least 30 glomeruli per animal from cell density was done by gel electrophoresis in agarose gels. RNA
per volume (NcV) and volume density of the cell type concentration was determined photometrically in triplicate.
(VcV) according to this equation: NcV 
 k/  Nc1.5A / RT-PCR for oligonucleotides. For ET1 the sense primer
Vc0.5V with  for podocytes 
 1.5 and for mesangial and was 5-TGGCTTTCCAAGGAGCTCC-3; the antisense
endothelial cells 
 1.4 and k 
 1 [22, 23]. primer was 5-GCTTGGCAGAAATTCCAGC-3, re-
sulting in a PCR fragment of 339 bp. The mutant com-Immunohistochemistry, RT-PCR, and nonradioactive
prised 302 bp. For TGF-, the sense primer was 5-TGGin situ hybridization
CTTTCCAAGGAGCTCC-3; the antisense primer was
Immunohistochemistry. Immunohistochemistry using 5-GCTTGGCAGAAATTCCAHC-3, resulting in a 403
an antibody against the proliferating cellular nuclear anti-
bp fragment. The mutant had a length of 300 bp. For
gen (PCNA, -PCNA monoclonal mouse; 1:150; Dako
PDGF we used the sense primer 5-CCTGTGCCCATTCo., Hamburg, Germany) and the avidin-biotin technique
CGCAGGAA-3 and the antisense primer 5-TTGGCwas performed on paraffin sections. For negative con-
CACCTTGACACTGCG-3. The fragment was 226 bptrols the first antibody was omitted [13, 18]. The sections
in length and the mutant comprised 183 bp.were then examined using light microscopy at a magnifi-
Reverse transcription and PCR. Reverse transcriptioncation of 400. The number of PCNA positive glomeru-
was performed according to the method of Paul et al aslar cells was counted per glomerular profile and area in 50
described in detail [25, 26]. The reaction was run on asystematically subsampled glomeruli [18]. The number of
Perkin Elmer DNA thermal cyler 480 (Perkin Elmer,tubular cells per mm2 tubulointerstitial area was counted on
Langen, Germany) under the following conditions: ini-50 systematically subsampled fields (0.1681 mm2), which
tial denaturation: 94	C, three minutes; 94	C, one minute;were distributed all over the cortical zone.
annealing: 55	C, one minute; extension: 72	C, one minute,RT-PCR and nonradioactive in situ hybridization (ISH).
26 to 28 cycles.Because of the well-known interaction between endo-
Competitive PCR. Quantification of ET1-, TGF--,thelin (ET) and the sympathetic system [24], ET-1 mRNA
and PDGF-mRNA was carried out using deletion mu-expression was investigated in five animals per group
tants of the respective cDNAs as internal standard [26].using RT-PCR and ISH as described later in this article.
Analysis of PCR fragments was done according to aSince in our previous article the expression of transform-
modification of the method of Paul et al as described ining growth factor- (TGF-) mRNA was lower after
detail [25, 26].treating SNX with the central sympatholytic agent moxo-
In situ hybridization for ET1, TGF-b, and PDGF mRNA.nidine [13], TGF- mRNA expression also was deter-
mined. In addition, mRNA expression of the platelet- To study the effect of - and -blockade and their combi-
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Fig. 2. Semithin sections showing represen-
tative changes of glomeruli in sham-operated
controls (A) and untreated (B) and treated
(C–E ) SNX. Glomerular enlargement with
hypertrophy and degeneration of podocytes
(arrows) and mesangial matrix accumulation
(*) is seen in untreated SNX (B) compared
to sham (A). These changes are ameliorated
in all three intervention groups (C–E). A, un-
treated sham; B, untreated SNX; C, phenoxy-
benzamine-treated SNX; D, metoprolol-treated
SNX; E, combination-treated SNX; magnifi-
cation: 1:680 (A and B) and 1:500 (C–E).
nation on ET1-, TGF--, and PDGF- mRNA expression, tylated [20 min, 0.25% acetic anhydride (vol/vol) in 0.1
mol/L triethanolamine, pH 8.0] to reduce nonspecific back-a nonradioactive ISH was performed.
Tissue preparation. Cryostat sections (10 m, silanized ground staining. Then the sections were dehydrated in
graded alcohols, air dried, and stored at20	C until use.slides) were fixed in 3% paraformaldehyde/PBS (pH 7.0,
5 min, 4	C). After deproteination, the sections were ace- Probe preparation and labeling. A 339 bp cDNA frag-
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Fig. 2 (Continued).
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ment of the ET-1 cDNA was obtained from a PCR prod-
uct using rat ET-1 specific primers after RT of rat kidney
total RNA [27]. A 403 bp fragment of the TGF- cDNA
encoding positions 1156 to 1559 of the rat TGF- gene
was received from a PCR product by using rat-specific
primers after RT [28]. The 226 bp cDNA fragment of
the PDGF cDNA encoded positions 282 to 506 of the
PDGF gene [29]. The segments encoding the relevant
positions of the genes were inserted into the pGEM-T
vector system (Promega Biotech., Madison, WI, USA).
Digoxigenin-labeled RNA probes were synthesized us-
ing a DIG RNA-labeling mix (Boehringer Mannheim
GmbH, Mannheim, Germany). Subsequently, the labeled
transcripts were ethanol-precipitated and resuspended in
DEPC-treated water. The integrity and size of the probes
were checked by running aliquots on a denaturating
formaldehyde gel beside RNA standards and blotting
them onto a nylon membrane. The transcript dilution
series of the labeling reactions and a labeled control
RNA (Boehringer Mannheim GmbH) were spotted on
nylon membranes, which were processed in a colorimet-
ric detection procedure.
In situ hybridization. The sections were hybridized
with 4 ng of labeled probe in buffer in a moist chamber.
Hybridization of the probe with native mRNA was al-
lowed for 18 hours at 50	C. Post-hybridization steps in-
cluded removal of unbound probe and two subsequent
washes in 2 SSC/50% formamide (1 hour, 50	C), RNase
A treatment (20 g/mL, 0.5 mol/L NaCl, 10 mmol/L Tris-
HCl, pH 8.0, 1 mmol/L EDTA, 30 min, 37	C) and washes
in 1  SSC (37	C, 10 min).
Immunohistological detection of hybridized probes. Af-
ter post-hybridization washes, the sections were equili-
brated in buffer I [13]. Nonspecific background staining
was blocked by incubation for one hour with 0.5% block-
ing reagent/buffer I (Boehringer Mannheim). The hy-
bridization products were visualized by enzyme-linked
immunosorbent assay (ELISA) using alkaline phospha-
tase-conjugated sheep anti-digoxigenin-Fab fragments
(Boehringer Mannheim; 750 U/mL, 1:300). Following
incubation at 4	C overnight, unbound conjugate was re-
moved by two washes in buffer I followed by equilibra-
tion of the sections in buffer II [13]. Nitro-blue tetra-
zolium and 5-bromo-4-chloro-3-indolyl phosphate served
as chromogen. Negative controls included hybridization
with the sense RNA probe, incubation without probe
for detection of unspecific binding of the primary anti-
body, and omission of both probe and primary antibody.
Statistics
Data are given as mean SD. Kruskal-Wallis test and
one-way analysis of variance (ANOVA), respectively,
were chosen for analysis of variance, followed by Dun-
can’s multiple-range test to determine whether the differ-
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Fig. 3. Representative ultrastructure of glo-
meruli in sham-operated control rats (A–C)
and untreated (D) and treated (E–G ) SNX.
Ultrastructural changes in untreated SNX (hy-
pertrophy of mesangial cells, mesangial matrix
deposition and podocyte hypertrophy with
signs of cell degeneration) were partly pre-
vented by all three treatments. A, untreated
sham; B, phenoxybenzamine-treated sham; C,
metoprolol-treated sham; D, untreated SNX;
E, phenoxybenzamine-treated SNX; F, meto-
prolol-treated SNX; G, combination-treated
SNX; magnification: 1:4000.
pothesis was rejected at P  0.05. Pearson’s correlation 18.4  1.63 g; SNX  C, 19.0  2.04 g; sham, 16.7 
analysis was used to analyze whether there was a correla- 1.13 g; sham  P, 17.5  1.63 g; sham  MET, 16.5 
tion between glomerulosclerosis and urinary albumin ex- 1.12 g; Table 1). Daily water intake was comparable in
cretion. the sham group (33.9  6.2 mL/day), the SNX  MET
(38.8  8.4 mL/day) and the SNX  C (39.6  8.3 mL/
day) group; it was significantly higher in untreated (50.4
RESULTS 4.2 mL/day) and PBZ-treated SNX animals (49  10.1
Animal data mL/day).
At the end of the experiment, body weight and hemo-Daily food intake was comparable in all groups (SNX,
18.5  2.01 g; SNX  P, 18.8  1.6 g; SNX  MET, globin were comparable in all seven groups. Absolute
Amann et al:  and b blockers in progressive renal failure1318
Table 4. Number of PCNA-positive glomerular and tubularand relative (factored for body weight) weight of residual
epithelial cellsrenal tissue (left kidney), MAP, SAP, and DAP (by tele-
PCNA-positive PCNA-positivemetric bp measurements) as well as serum creatinine
glomerular cells tubular epithelial(SCr) and serum urea (Surea) concentrations were signifi- per mm2 cells per mm2
cantly higher after SNX with no differences between the glomerular tubulointerstitial
Groups capillary area areaSNX groups (MAP: SNX, 105  13.3 mm Hg; SNX 
PBZ, 111  16.9 mm Hg; SNX  MET, 111  10.5 Sham operated
Untreated (N
8) 55.58.51 5.012.79mm Hg). Heart rates were comparable in sham (317 
PBZ (N
5) 27.59.09 6.471.7544 bpm), untreated SNX (316  31 bpm), SNX  PBZ
MET (N
5) 24.710.1 8.391.68(308  38 bpm), and SNX  MET (316  49 bpm). SNX
Using tail plethysmography, systolic BP was comparable Untreated (N
10) 16633.3a 12743.0a
PBZ (N
10) 49.18.19b 41.812.1abin all experimental groups at the beginning of the experi-
MET (N
10) 44.110.2b 39.816.7abment. There were no significant differences between un-
PBZMET (N
12) 41.512.9b 52.813.2ab
treated SNX and the three intervention groups at week P value ANOVA 0.001 0.001
2 (SNX, 96  16.6 mm Hg; SNX  MET, 91  7.4 Abbreviations are: PBZ, phenoxybenzamine; MET, metoprolol.
a P  0.05 vs. shammm Hg; SNX  PBZ, 90  33.7 mm Hg; SNX  combi-
a P  0.05 vs. SNXnation, 90  12.9 mm Hg) and week 11, respectively
(Table 1).
cantly higher in untreated SNX than in sham. MesangialMorphological investigations
cells hypertrophy was ameliorated but not completelyThe indices of glomerulosclerosis, tubulointerstitial
normalized by treatment with MET and combination,and vascular damage were significantly higher after SNX
whereas PBZ did not show a significant effect. Hypertro-(Fig. 1 and Table 2). Treatment of SNX with metoprolol
phy of endothelial cells was only significantly prevented(Fig. 1F) and combination therapy (Fig. 1G) significantly
by the combination therapy.lowered the glomerulosclerosis index. In contrast, tubu-
lointerstitial and vascular damage in SNX were some-
Qualitative electron microscopywhat lower with the different treatments but this was
Qualitative electron microscopical investigations ofnot statistically significant. The total number of glomeruli
non-sclerotic glomeruli showed marked alteration of glo-per kidney was significantly lower in all SNX groups
than in sham. The total glomerular volume per left kid- merular ultrastructure in untreated SNX (Fig. 3D) com-
ney—as an index of compensation after SNX achieved pared with sham, that is, mesangial matrix accumulation
by glomerular enlargement—was comparable. Mean glo- as well as degenerative changes of podocytes (hypertro-
merular volume was significantly higher in SNX than in phy, effacement of foot processes, pseudocyst formation,
sham-operated rats. Glomerular enlargement was less vacuolization). Glomerular ultrastructure was partly pre-
with all treatments and this was statistically significant served by all three treatments (Figs. 3E–G).
for phenoxybenzamine and combination treatment.
Urinary albumin excretion rate
Semithin sections
At the end of the study, urinary albumin excretion
Length density of glomerular capillaries, a marker of rate was significantly higher in untreated SNX than in
capillary obliteration, was significantly lower in untreated all sham-operated groups (Table 1). It was significantly
SNX compared to sham (Fig. 2 and Table 3). It was lower, however, in SNX treated with phenoxybenza-
significantly higher and no longer different from sham mine, metoprolol, and their combination compared with
in all three intervention groups (Fig. 2). The same was untreated SNX. Urinary albumin excretion showed atrue for the total capillary length per kidney.
significant correlation with glomerulosclerosis index (r
The mean number of podocytes per glomerulus was
0.59, P  0.001). In our previous study [13], which usedsignificantly lower and mean podocyte volume signifi-
the same animal model investigated in our current study,cantly higher in untreated SNX (Fig. 2B) than in sham
the time course measurements of urinary albumin excre-(Fig. 2A), indicating hypertrophy and loss of podocytes
tion in SNX and sham animals found that albuminuriaduring glomerular enlargement and glomerulosclerosis.
was progressive during the 12-week time course. TheThe podocyte number was significantly higher when
difference between untreated SNX and sham, however,SNX were treated with the three interventions (Figs.
was highest at the end of the experiment.2C–E). In contrast, podocyte hypertrophy was not amel-
iorated by the three treatments.
PCNA immunohistochemistryThe mean number of mesangial and endothelial cells
The absolute number of PCNA positive cells per glo-per glomerulus was not significantly higher in untreated
merulus (20 2.63) was significantly higher in untreatedSNX compared with sham. In contrast, mean mesangial
(246%) and endothelial cell (197%) volume were signifi- SNX compared with sham-operated controls (5.46 
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Fig. 4. Representative PCNA positivity of
glomerular cells. The number of PCNA-posi-
tive glomerular cells was significantly higher
in untreated SNX (E) than in all sham groups
(A–C ) and treated SNX (F–H), respectively.
A, untreated sham; B, phenoxybenzamine-
treated sham; C, metoprolol-treated sham; D,
negative control (by omitting the primary anti-
body); E, untreated SNX; F, phenoxybenza-
mine-treated SNX; G, metoprolol-treated SNX;
H, combination-treated SNX; magnification:
1:100.
0.06; Table 4 and Fig. 4). It was significantly lower, how- note that PCNA positivity was nearly completely re-
ever, in SNX treated with PBZ (7.45  0.51), MET stricted to visceral epithelial cells.
(6.23  1.33), and their combination (6.52  2.0) than
RT-PCRin untreated SNX (Fig. 5). The same was true for the
relative number of PCNA-positive glomerular cells (that Using specific primers, total renal ET-1, TGF- and
PDGF mRNA expression was found to be not signifi-is, per glomerular area) as well as for the absolute and
relative (that is, per mm2 of tissue) number of PCNA- cantly different in whole tissue samples of untreated and
treated SNX animals (Table 5).positive tubular cells (Table 4). In this context, it is of
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Fig. 5. Effect of subtotal nephrectomy and sym-
pathetic blockade on glomerular endothelin-1
(ET-1) mRNA expression by nonradioactive
in situ hybridization. ET-1 mRNA expression
was increased in untreated SNX (D) and phe-
noxybenzamine-treated SNX (E ) compared
with untreated (A) and treated (B and C )
sham-operated rats. ET-1 expression was
lower in glomeruli of SNX treated with either
the blocker metoprolol (F ) or a combination
of  and  blockers (G ). Magnification: 1:60.
Nonradioactive in situ hybridization treatment (Fig. 5G), glomerular ET-1 mRNA expression
was less intense. In contrast, tubulointerstitial and peri-Glomerular and tubulointerstitial expression of TGF--
vascular expression of ET-1 mRNA was comparable inand PDGF-mRNA was not different in sham, untreated
the seven experimental groups.and treated SNX (data not shown). Glomerular in situ
expression of ET-1 mRNA, however, was slightly in-
creased in untreated SNX compared to sham operated
DISCUSSIONcontrols. No infiltrating cells were detected in the glo-
The salient results of the present study are the amelio-meruli. ET-1 mRNA expression was strongest in visceral
ration of the glomerulosclerosis index and, to a lesserglomerular epithelial cells and presumably mesangial
extent, of the indices of interstitial and vascular damagecells; ET-1 mRNA expression did not correlate with the
by non-hypotensive doses of the  blocker,  blocker,degree of glomerulosclerosis. In the SNX treated with
MET (Fig. 5F), particularly in SNX with the combination and their combination. This was accompanied by a mod-
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Table 5. Expression of ET-1, TGF-, and PDGF mRNA by RT-PCR blood pressure lowering. These doses were selected on
the basis of a pilot study that had indicated no decreaseET-1 TGF- PDGF
in blood pressure with the doses used. Lowering of bloodGroups Ratio probe/mutant
pressure would have been of concern since blood pres-
Sham operated
sure is one of the most potent determinants of progres-Untreated (N
8) 0.820.31 0.980.42 4.721.70
PBZ (N
5) 0.880.25 0.670.08 3.891.29 sion; therefore, we used telemetry, a state-of-the-art
MET (N
5) 0.700.31 0.860.31 3.261.50 technique to exclude changes in blood pressure [31]. We
SNX must acknowledge, however, that since intraglomerularUntreated (N
10) 0.970.88 1.160.86 2.311.56
pressure was not measured, changes in intrarenal resis-PBZ (N
10) 1.070.56 1.410.74 2.460.86
MET (N
10) 1.090.56 1.260.47 2.960.82 tance and thus intrarenal hemodynamic effects of the
PBZMET (N
12) 1.641.29 2.001.0 3.522.14 treatments cannot be excluded.P value ANOVA NS NS NS
The end points of the present study were quantitative
Abbreviations are: ET-1, endothelin-1; TGF-, transforming growth factor-;
glomerular histology and albuminuria. The latter wasPDGF, platelet-derived growth factor; PBZ, phenoxybenzamine; MET, meto-
prolol. measured to evaluate the in vivo relevance of the find-
ings. The significant decrease of albuminuria after treat-
ment introduces a difficulty in interpretation, since pro-
teinuria has been identified as a potent promotor ofest reduction of mean glomerular volume and of the num-
progression [32]. Consequently, the question of whetherber of PCNA-positive cells, that is, activated or prolif-
lowering proteinuria is simply a passive reflection of lesserating glomerular and tubular epithelial cells. A highly
glomerular damage or a causal factor involved in thesignificant effect of the - and -adrenoreceptor block-
attenuation of progression remains unknown.ade was seen on glomerular capillary length density as
Podocytes have catecholamine receptors [33–35] anda novel and sensitive index of capillary obliteration (or
damage to podocytes is the accepted initial step in thealternatively capillary growth that had remained inade-
development of glomerulosclerosis [36]. Indeed, podo-quate in relation to glomerular enlargement). Similarly,
cyte structure as assessed by electron microscopy wasthe decreased number of podocytes in the untreated SNX
altered in untreated subtotally nephrectomized rats andanimals reflected a loss of these cells. This was almost
was partially preserved by all sympatholytic treatments.completely prevented by the - or -receptor blockade.
This intervention also prevented the loss of podocytes.Finally, a significantly lower urinary albumin excretion
Indirect effects, mediated via abrogation of  receptorrate was seen in the treated compared to the untreated
stimulated generation of angiotensin II (Ang II), cannotSNX groups. Although alternative explanations are not
be excluded, however.totally excluded, the results are compatible with the no-
The present study complements a preceding experi-tion that sympathetic activation via release of catechola-
ment in which a central sympathoplegic agent, moxoni-mines promotes progression independently of systemic
dine, was administered to subtotally nephrectomizedBP in this model of noninflammatory renal damage.
rats. Cotransmitters are coreleased from sympatheticThe methodology that was adopted deserves com-
nerve endings together with catecholamines, that is, ATPment. We intentionally resected only a limited amount
and NPY [37], and thus, the beneficial effect of moxo-of the left kidney that had undergone hypertrophy after
nidin in the previous study did not permit a conclusionuninephrectomy. This avoids several confounding fac-
that it was actually the catecholamines that influencedtors encountered in advanced renal failure, for example,
progression. Of particular concern was the potential re-severe hypertension, hypervolemia, and acidosis. Conse-
lease of ATP, which has been shown to activate renalquently, anemia was absent and only a minor increase
cells [35]. Moreover, blockade of presynaptic-receptorsin BP was seen.
has been shown to enhance noradrenaline and ATP re-Although a pair-feeding protocol could not be used
lease in rat kidney [38, 39]. Thus, unopposed proliferativebecause of the considerable number of parallel groups,
effects of these renal neurotransmitters mediated via water and food consumption was monitored and intake
adjusted so as to keep the body weight in the different adrenoceptors [40] and purinergic receptors [35, 41] may
have masked the beneficial effects, especially in thegroups comparable, thus eliminating further potential
confounding factors. This protocol also guaranteed con- group of rats receiving only the  blocker.
The most effective intervention was combined - andtrolled intake of medication.
Surgical resection creates a low renin model of pro- -adrenergic blockade. It is uncertain whether dimin-
ished -adrenergic release of renin is involved in thegression of renal failure [30]. Consequently, the results
of the present study cannot necessarily be extrapolated effect of  blockade or whether this is explained by
the blockade of noradrenaline action via -adrenergicto high renin models of renal damage, for example after
ligation of renal arteries. stimulation of renal cells. Stimulation of the synthesis of
renin and Ang II may not only occur in the juxtaglomeru-Low doses of the adrenoreceptor blockers were inten-
tionally selected to avoid the confounding effects of lar apparatus, but also locally in the injured proximal
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